Breakthroughs in Alzheimer’s Disease Assessment: Quantitation of CSF Beta Amyloid 40 & 42
Description: Dr Clarke discusses the advantages in assessing Alzheimer’s disease by measurement of amyloid beta 42/40 ratio, describes an improved LC-MS/MS approach for quantitating amyloid beta and Apolipoprotein E phenotyping and its advantages over ELISA platforms, and reviews a new, comprehensive metric that assesses a patient’s overall risk of developing Alzheimer’s disease, represented by a total hazards ratio.
At the conclusion of this program, participants will be able to:
- Discuss the advantages in assessing Alzheimer’s disease risk by measurement of the amyloid beta 42/40 ratio
- Describe an improved LC-MS/MS approach for amyloid beta 42/40 quantitation and Apolipoprotein E phenotyping, and discuss the potential advantages of this approach relative to ELISA platforms
- Review a new, comprehensive “risk assessment score” used to assess a patient’s risk of having Alzheimer’s disease
ASCLS P.A.C.E.® credits are available to laboratory professionals through November 24, 2017.